Biotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.
With shares pulling back after a capital raise, this strategy offers double-digit upside potential in addition to downside protection of more than 20%.
Goldman Recommends 2 Small-Cap SaaS Plays Amid Dot-Com Boom Revival
Goldman Sachs has highlighted two intriguing small-cap names as AI valuations get crazier.
Why I’m Eyeing Prices, Biotech and AI in Q3
As the second quarter skims some froth off the technology trade, let’s see why these three areas are key to watch in Q3.
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
When the ‘AI Inflation’ Hits the Fan
Rising costs associated with AI are weighing on stocks like Apple. But there’s a bigger question looming for hyperscalers.
Cracks in the AI Narrative? Margins Suddenly Matter
SpaceX is round-tripping, Cerebras is getting marked down on margins, and concerns grow around OpenAI and Anthropic.
This Biotech Could Become a ‘Sleeper’ Hit
Let’s look at this rising biopharma name working on several neurological condition treatments.
An Option Strategy for a Small-Cap Healthcare Name
Several insiders purchased just over 180,000 shares in total during mid-May, always a nice vote of confidence.
Careful Where You Step in This Market
Tech is looking stretched, housing is looking weak and SpaceX is blasting past powerhouses like Amazon as other AI companies line up to go public.
A Market Verging on the Absurd
As an Iran deal has landed (for real this time?) and SpaceX has taken off to a wild valuation, here’s my take on the market now.